Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Burkitt Lymphoma 19Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Leukemia 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Blast Crisis 2Recurrence 1Philadelphia Chromosome 1Neoplasm, Residual 1Lymphoma 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Down Syndrome 1

Interventions

Cyclophosphamide 3Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Biopsy 2pirtobrutinib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1ibrutinib 1fludarabine phosphate 1fludarabine 1blinatumomab 1Thiotepa 1Surveys and Questionnaires 1Sirolimus 1Mycophenolic Acid 1Methotrexate 1Cyclosporins 1Cyclosporine 1Busulfan 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Lymphoid × blinatumomab × Clear all
NCT06111625 2023-11-01

Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL

Sichuan University

Phase 2 Recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Lymphoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡